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Abstract
Background: Ascorbic acid (AA), or Vitamin C, is most well known as a nutritional supplement with antioxidant properties.
Recently, we demonstrated that high concentrations of AA act on PMP22 gene expression and partially correct the Charcot-
Marie-Tooth disease phenotype in a mouse model. This is due to the capacity of AA, but not other antioxidants, to down-
modulate cAMP intracellular concentration by a competitive inhibition of the adenylate cyclase enzymatic activity. Because
of the critical role of cAMP in intracellular signalling, we decided to explore the possibility that ascorbic acid could modulate
the expression of other genes.
Methods and Findings: Using human pangenomic microarrays, we found that AA inhibited the expression of two categories
of genes necessary for cell cycle progression, tRNA synthetases and translation initiation factor subunits. In in vitro assays, we
demonstratedthat AA induced the S-phase arrest of proliferative normal and tumor cells.Highest concentrations of AA leaded
to necrotic cell death. However, quiescent cells were not susceptible to AA toxicity, suggesting the blockage of protein
synthesis was mainly detrimental in metabolically-active cells. Using animal models, we found that high concentrations of AA
inhibited tumor progression in nude mice grafted with HT29 cells (derived from human colon carcinoma). Consistently,
expression of tRNA synthetases and ieF2 appeared to be specifically decreased in tumors upon AA treatment.
Conclusions: AA has an antiproliferative activity, at elevated concentration that could be obtained using IV injection. This
activity has been observed in vitro as well in vivo and likely results from the inhibition of expression of genes involved in
protein synthesis. Implications for a clinical use in anticancer therapies will be discussed.
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Introduction
For a long time, ascorbic acid (AA) has been described as a
molecule absolutely required for the integrity and normal life span
in mammalians. Most of princeps studies have been derived from
the observation on patients suffering from scurvy. Numerous
articles have been published demonstrating the necessity of
supplement human nutrition with AA, either originating from
foods or from nutrition complements. Different biochemical
properties have been attributed to AA, essentially in relation with
its well-documented antioxidant activity. However, little is known
about the effects of AA treatment on gene expression.
In previous studies we showed that high concentrations of AA
down-regulate the cAMP-dependent expression of PMP22,
partially correcting Charcot-Marie Tooth disease phenotype in
mouse models [1]. In additional experiments, we demonstrated
this action relies on the AA-induced reduction of intracellular pool
of cAMP [2]. Importantly, other antioxidants like retinol and a-
tocopherol were unable to modulate the pool [3], strongly
suggesting the inhibitory effect of AA was unrelated to its
antioxidant properties. Indeed, we have recently reported that
AA is a competitive inhibitor of adenylate cyclase, probably due to
partial three-dimensional structures similitude between AA and
ATP [4].
Because of the critical role of cAMP in the modulation of gene
expression, we sought to determine whether other genes could be
sensitive to AA treatment. We conducted a series of in vitro and in vivo
experiments using varying concentrations of AA. We first analyzed
the impact on gene expression using human pangenomic micro-
arrays. As we found that several genes implicated in cell proliferation
were underexpressed in presence of AA, we further analyzed the
effect of AA administration on cell division and tumor progression.
Data presented here stronglyindicate that AA has an antiproliferative
activity, potentially due to the inhibition of expression of genes
involvedincelldivisionprogressionandmayberelatedtoitsactionas
a ‘‘global regulator’’ of intracellular cAMP pool.
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Cells and culture conditions
The human skin fibroblast cell line was obtained from the
Coriell Cell Repository. All others cells were purchased from the
American type Culture Collection. Cells were grown according to
the manufacturer’s instructions in RPMI 1640 with 25 mM
HEPES supplemented with 15% fetal bovine serum (GIBCO) at
37uC in 5% CO2/95% air. Cells were counted on a microscope
(106 objective) using a Neubauer hemocytometer. Cell viability
was estimated using trypan blue staining.
AA Treatment
L(+) ascorbic acid (99.7%, Riedel-de-Hae ¨n) was dissolved as
needed in 16 PBS and then filtered. It was added to a final
concentration of 50 mg/ml in pH 7 medium supplemented with
25 mM HEPES.
RNA extraction and analysis
Following the incubation period, total RNA was extracted from
cells using TRIZOL reagent (Invitrogen) in accordance with the
manufacturer’s instructions. To ensure the integrity of the RNA
prior to use, the quality and concentration of each sample was
tested using an Agilent 2100 Bioanalyzer.
Hybridization and microarray scanning
The following materials were purchased from Agilent Technol-
ogies: Low RNA Input Fluorescent Linear Amplification Kit, in
situ hybridization kit, and 60-mer human oligomicroarray kit. The
reverse transcription labelling reactions and hybridizations
essentially followed the protocol recommended by Agilent
Technologies version 4.1 (2004).
Briefly, a 500-ng aliquot of each total RNA sample was reverse
transcribed into cDNA using an oligo(dT) primer.
The reaction was carried out in a solution containing 500 mM
dNTP and 400 U MMLV reverse transcriptase at 40uC for 2 h,
and then terminated by incubation at 65uC for 15 min. Reverse
transcription and incorporation were performed at 40uC for 2 h in
a mixture containing either 400 mM cyanine 5-carbamylated
protein (Cy3 for the untreated samples) or 400 mM cyanine 5-
carbamylated protein (Cy5 for the treated samples), the transcrip-
tion mix, and T7 RNA polymerase. RNeasy spin columns
(Qiagen) were used according to the manufacturer’s protocol to
purify the amplified labelled cDNA samples. Hybridization was
carried out in 440 ml of mixture containing 750 ng of Cy3- and
Cy5-labeled cDNA probes, control targets, and the fragmented
DNA supplied by the manufacturer at 60uC for 17 h. The
microarrays were then washed according to the manufacturer’s
protocol, dried, and scanned using an Agilent microarray scanner
with 532 nm laser for Cy3 measurement and a 635 nm laser for
Cy5 measurement. The results were analyzed using the Luminator
Bioinformatics platform (Rosetta Biosoftware). Results have been
deposited in MIAMExpress data base (accession number E-
MEXP-1861).
Reverse transcriptase-PCR analysis
To confirm the gene expression patterns observed on the
microarrays we verified gene expression levels following AA
treatment at each concentration by quantitative reverse transcrip-
tase-PCR using the Light Cycler 480 Real-Time PCR System
(Roche) with universal probe library (UPL). Two micrograms of
total RNA from each sample were reverse transcribed using
Superscript II reverse transcriptase (Invitrogen) to produce cDNA.
Human b-actin (ACTB) and 18S human ribosomal DNA were
used for data normalization. The results were treated using the
comparative CT method, where the amount of the target,
normalized to the endogenous reference and relative to a
calibrator, is given by 2
2DDCT [5]. (An asterisk indicates a P
value,0,05).
Cell cycle and death analysis—flow cytometry
To determine the cell cycle status after treatment, we stained
cells (10
6 cells/condition) with 50 mg of propidium iodide and
subsequently analyzed the DNA content by fluorescence-activated
cell sorting (FACS). All cell cycle results were analyzed using the
ModFit Software provided with the FACSCalibur flow cytometer.
The relative cell cycle distribution was calculated using the FIT
option. The same process was repeated for all samples.
To determine cell death, we used the Vybrant Apoptosis Assay
Kit #2 (Invitrogen) (10
5 cells/condition). The cell cycle distribu-
tion and the apoptosis assay were analyzed using ELITE Flow
Cytometry (Beckman Coulter) and Cell Quest software. Duplicate
assays were performed in all cases.
Animal studies
The antiproliferative action of ascorbic acid was investigated in
the HT29 xenograft mouse model. Mouse care followed the
animal welfare guidelines of our institution, and local animal ethics
committee approval was obtained prior to starting the experi-
ments. Four-week-old female BalbC nude mice (Charles River,
Lyon, France) (n=7 per group) were subcutaneously inoculated
with 1610
6 HT29 cells on the right flank. Ten days after implant,
and once tumors had reached sizes that could be measured
accurately, mice were treated with AA at the following doses:
15 mg/kg, 100 mg/kg, or 1,000 mg/kg. Drugs were administered
intraperitoneally on a daily basis for 1 month. Tumor size was
measured every 2 days in three dimensions using Vernier calipers,
and tumor weight (g) was calculated using an ellipsoid shape to
approximate the tumor mass: m=p/66length6width6height.
Studies were terminated after 30 days of treatment. Surviving
mice have been sacrificed, and tumor weight evaluated. In
addition, the date and number of surviving animals were recorded
for surviving analysis.
Statistical analysis
We used Prism v5 software to perform the statistical analysis.
For tumor weight analysis we used the Mann-Whitney two-tailed
statistical significance test, with a confidence interval of 95%. For
the survival study the Kaplan-Meier method and log-rank tests
were used. We considered a P value lower than 0.05 as significant.
Results
AA and gene expression
Primary cultures of normal human fibroblasts were treated for
24 h with three different concentrations of AA, ranging from
0.3 mM to 0.8 mM. RNAs were then extracted, reverse
transcribed, and hybridized on AGILENT human pangenomic
microarrays. RNA samples from untreated cells were labelled with
Cy3, and those from treated cells were labelled with Cy5. In a
reciprocal experiment, the dye labels were switched, so that
untreated cells were labelled with Cy5 and treated cells with Cy3.
Genes that were over- or under expressed in the initial screen and
behaved in a reciprocal manner in the second screen (e.g., under
expressed in the first screen and over expressed in the second
screen) were selected and included in a minilibrary. Data were
analyzed using Rosetta bioinformatics software. We considered
only genes that varied in the same direction (up or down-
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stringent criteria, we found that only a few genes were over
expressed in cells incubated with AA, without an obvious
biological function. In contrast, 31 genes appeared to be down
regulated (Table S1). Of these 31 genes, 12 code for members of
two protein families: tRNA synthetases and translation initiation
factor subunits (Fig. 1a). These data were confirmed using qPCR
(Fig. 1b).
AA and in vitro cell division
Both tRNA synthetases and translation initiation factor subunits
are involved in protein synthesis and cell cycle progression in
prokaryotes, basic eukaryotes, and mammals [6-11]. To determine
whether AA had an impact on cell proliferation, we treated the
same type of fibroblasts used in microarray assays with increasing
concentrations of the drug and monitored the growth curves
(Fig. 2a). At moderate concentration (0,3 mM), AA partially
inhibited cell proliferation. Higher concentrations (0.6 and 2mM)
respectively resulted in a cell proliferation arrest or cellular death.
We then tested the effect of AA on cell lines derived from human
cancers. Cell growth was affected by AA treatment in all of the cell
lines, although sensitivity varied (Fig. 2b, Tables S2-S3). This
difference is not understood at present. It may be related, at least
in part, to varying AA uptake between cell lines since Raji cells,
which are the most sensitive cells to AA treatment, also express the
highest level of sodium-dependent vitamin C transporter 2
(SVCT2) mRNA (data not shown). In addition to the experiments
above, we confirmed the effect of AA on cell division using a BrdU
incorporation test (data not shown).
To evaluate the potential reversibility of the effect, cells
incubated with increasing AA concentrations were either collected
24 h later, washed and cultured in AA-free medium, or let in
presence of the drug for the next three days. We observed that the
partial inhibition of cell division obtained with 0.6 mM of AA
could be reversed (Fig. 2c). However, with AA doses enable to
induce cell death (2 mM and 3 mM), cells continued to die even
after the AA-containing medium was removed (Fig. 2d,e).
Cell cycle profiles were analyzed by FACS to determine at which
stage of cell division the cells treated with AA were blocked. We
noted that 3 mM AA caused a growth arrest during S phase in
healthy fibroblasts cells (Fig. 3a) as well as in Raji cells (Fig. 3b, c),
with no cells detected in G2/M. In addition, we observed a
significantincreaseincell death,which weconfirmedbytrepanblue
uptake (Fig. 4a). To determine the type of cell death induced by AA
treatment, we used flow cytometry on Raji cells, either double
labelling with Annexin V (to identify the early apoptotic phase
characterized by the external membrane phosphatidylserine
translocation) and propidium iodide labelling (to identify plasma
Figure 1. Human pangenomic microarrays and qPCR analysis. (a) Primary cultures of human skin fibroblasts were incubated in medium
containing 0, 0.3, 0.6, and 0.8 mM AA. After 24 h, RNA was extracted; reverse transcribed, and hybridized on AGILENT human pangenomic
microarrays. Dye swap experiments were also conducted. Data were analyzed using the Rosetta Luminator software package. And only those genes
that were up- or downregulated in AA-treated cells were analyzed further. Among the downregulated genes, 40% belong to two classes (tRNA
synthetases and translation initiation factor subunits) involved in protein synthesis. (b) Validation of microarray results using qPCR and Roche UPL-
specific probes.
doi:10.1371/journal.pone.0004409.g001
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using a TUNEL enzymatic labelling assay of apoptosis (Fig. S1a).
Nearly all of the cells treated with increasing concentrations of AA
became necrotic, without an increase in apoptosis. This was
confirmed by the typical swelling and bubbling morphology of the
necrotic cells (Fig. 4c, d). When we treated quiescent cells (human
primary fibroblasts at confluence) with the same concentration of
AA, there was no effect (Fig. S1b). This data indicates that only
actively proliferating cells are affected by AA treatment, and that
cells arenot dying from toxicity induced by high AA concentrations.
Figure 2. Impact of AA treatment on cell growth. Growth curves of healthy human fibroblasts (a) or Raji cells (b) incubated with various AA
concentrations. Cell density estimation of the reversal of AA treatment on Raji cells incubated with 0.6 mM (c),2m M(d),o r3m M(e) AA.
doi:10.1371/journal.pone.0004409.g002
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To test the potential effect of AA treatment in vivo, human tumor
cells were implanted by subcutaneous injection in nude mice.
Colon adenocarcinoma cells (HT29) have been used since they
were sensitive to AA treatment in vitro (Fig. S1c). Four groups of 7
grafted mice presenting visible tumors, 10 days post-implantation,
were randomly separated. Animals were given a daily intraper-
itoneal injection during 1 month, containing either a placebo
solution or AA in concentrations ranging from 15 mg/kg/d to
1000 mg/kg/d. Tumor size was evaluated every two days for
1 month (Fig. 5a). After 1 month, surviving mice were sacrificed
and tumor weight was evaluated (Fig. 5b and Table S4).
Tumor growth was clearlyreduced in animalsreceiving the highest
concentration of AA (1000 mg/kg/d) when compared to the placebo
group (Fig. 5a, b). All of the seven grafted mice in the 1000 mg/kg/d
group were alive at the end of 1 month (Fig. 5c). On the contrary,
tumor growth was not affected in the 15 mg/kg/d group (Fig. 5 b).
Moreover, only three of the seven grafted mice were still alive at the
end of the assay the others having died abruptly during the
experiment (Fig. 5c). An intermediate situation was observed in
animal treated with 100 mg/kg/d (Fig. 5b and c). A summary is
presented in Table S4. The exact cause of death in animal cohorts
treated either with the lower AA concentration or placebo is not easy
to define. However, autopsies of animals sacrificed after 30 days or
from spontaneous dead animals, revealed a massive metastatic spread
with peritoneal (Fig. S2a and S2b) as well as peri hepatic carcinosis
(Fig. S2c). Therefore, we propose that spontaneous death of animals
that have not been treated with the highest dose of AA is due to a
highly invasive carcinogenic process that is not observed in animals
treated with 1000 mg/days. This suggests that AA could also protect
from metastatic invasion, although this hypothesis should be
confirmed in further experiments.
At the end of the treatment period, total RNAs were extracted
after tumor dissection, and subjected to RT-qPCR to evaluate the
deregulation of the gene expression. Consistently with the data
obtained in vitro, tRNA synthetase and translation initiation factor
subunits genes were under expressed in grafted tumors after AA
treatment, in a dose-dependent manner (Fig. 5d). Hence we
demonstrated that AA inhibits the expression of the same genes in
vitro as well as in vivo.
Discussion
Ascorbic acid is most well known as Vitamin C, the nutritional
supplement essential for preventing scurvy. The recommended
daily dose has varied over time, but it is presently about 75 to
90 mg/day. However, several authors, Linus Pauling among
them, have suggested that higher daily doses might prevent cancer
[12]. This has been a hotly debated topic in the scientific
community. Although several papers have described the effect of
Figure 3. Cell cycle analysis. Cell cycles in control and treated human primary fibroblasts (a) or Raji cells (b), were analyzed using propidium
iodide. DNA content was analyzed using FACS to determine the cell cycle distribution. All cell cycle results were analyzed using the ModFit software
provided with the FACSCalibur flow cytometer. The FACS profile is shown in (c).
doi:10.1371/journal.pone.0004409.g003
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always ascribed to the antioxidant properties of AA [13].
Based on the experiments described in this paper, we propose that
AA inhibits cell division and further promotes necrosis by down-
modulatingtheexpressionofgenesnecessaryforS-phaseprogression.
We found that actively proliferating but not quiescent cells are
susceptible to AA treatment, excluding an non-specific toxicity of the
highest AA concentrations. It is tempting to speculate the inhibited
expression of tRNA synthetases and translation initiation elongation
factor subunits leads to the rapid cessation of energy production in
proliferating cells, resulting in necrotic cell death.
We have recently demonstrated that ascorbic acid is a
competitive inhibitor of adenylate cyclase activity [4], resulting
in a decrease of intracellular cAMP concentration. However, the
mechanism underlying the regulation of tRNA synthetase and ieF
subunits expression in mammalian cells are still unknown. In
particular, the role of cAMP remains to be clarified.
Few experiments using animal models, with spontaneous
tumors, have been performed. These studies, using an oral AA
administration, report a decreased mortality for treated animals
[16]. In humans, clinical trials results are mixed; some studies
indicate a benefit to patients treated with AA [17], while others do
not reveal any beneficial effect following AA treatment [18,19].
We may note that positive trials involved IV injection, in contrast
with negative results that involved oral administration. From data
presented in this manuscript, it is obvious that treatment with
increasing doses of AA induces a specific down regulation of
expression of a selected set of genes, resulting in an arrest of cell
proliferation and, at higher doses, in cell death.
Treatment of xenografted animals, either with a placebo or with
increasing doses of AA, allowed us to draw some conclusions:
1 - Treatment with high doses of AA results in a lowering of
tumor progression in terms of tumor weight.
Figure 4. Cell viability analysis. (a) Cell viability of Raji cells treated with varying concentrations of AA was evaluated using trypan blue staining.
(b) The same cells were analyzed using a propidium iodide (PI) /Annexin-V double label (see Methods). ELITE Flow Cytometry (Beckman Coulter) and
Cell Quest software was used to analyze the different cell populations. Morphology of untreated (c) and treated (3mM AA) (d) colon adenocarcinoma
(HT29) cells. Cells were observed with a light microscope using the phase contrast setting.
doi:10.1371/journal.pone.0004409.g004
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survive after 40 days (30 days of treatment plus 10 days of
grafting). We have no explanation but we observed numerous
carcinogenic invasion, in placebo treated animals and in
animals treated with lower doses of AA. In contrast, animals
treated with 1000 mg/days did not present carcinogenic
invasion. It has been described in the literature [20-22] that
HT29 cells are able to form metastatic carcinogenic colonies (in
colon and liver). In addition, Tremblay et al demonstrate that
HT29 are able to perform diapedesis.
3 - Genes that have been demonstrated to be down regulated in
cellular in vitro experiments have also been found to be down
regulated in vivo, and more precisely in tumors.
In conclusion, in terms of anticancer therapy, it appears that AA
treatment will only be effective if a high enough concentration of
Figure 5. Tumor growth and weight evaluation. Kaplan Meier survival curves. Gene expression in tumor. HT29 cells were injected into
nude male mice. Mice presenting with a tumor after 10 days were treated every day with either a placebo (physiological serum) or one of three AA
concentrations. (a) Tumor growth in placebo-treated mice and mice treated with a daily intraperitoneal injection of AA (1000 mg/kg/d). (b) Mice
were sacrificed after 1 month of a daily AA treatment and tumors were weighted to determine the effect of AA treatment. An asterisk indicates a P
value,0,05. (c) Kaplan-Meier survival curves of mice treated with placebo or with 15 mg/kg/d, 100 mg/kg/d, or 1000 mg/kg/d AA. Once visible
tumors were established (10 days after injection) mice were randomized and treated either with ascorbic acid or with placebo. Comparison of
placebo treated curve and 1000 mg/kg/d treated animals, using a long rank statistical test, indicates a high statistical significance (P value=0.0022).
(d) Relative quantification of mRNA coding for tRNA synthetase and a translation initiation factor subunit using qPCR technology and Universal Probe
Library (Roche). An asterisk indicates a P value,0,05.
doi:10.1371/journal.pone.0004409.g005
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published data from healthy volunteers [23], high concentrations
may only be reached by intravenous injection. These high doses
have been found not to be toxic in animal as well as in human
[24,25]. Clinical trials in which patients, with advanced cancer,
receiving injections of high AA doses would shed some light on the
therapeutic utility of AA.
Supporting Information
Figure S1 Tunnel enzymatic labelling assay and cell density
analysis in cellular junction conditions. (a) Detection and
quantification of apoptotic cells by a TUNEL assay using the In-
Situ Cell Death Detection Kit, TMR red (Roche Applied Science)
in accordance with the manufacturer’s instructions. Analyses of
apoptosis following treatment with two different AA concentra-
tions (0.6 mM and 2 mM) were conducted on human primary
fibroblasts. (b) Analysis the effect of increasing amounts of AA on
confluent cultures of human primary fibroblasts. (c) Growth curves
of HT29 cells (evaluated using a Neubauer hemocytometer)
incubated with either 3 mM of AA or medium containing no AA.
Found at: doi:10.1371/journal.pone.0004409.s001 (0.85 MB EPS)
Figure S2 Animals treated with a placebo, have been sacrificed
after 30 days of treatment (plus 10 days of grafting) and autopsied.
All animals present either peritoneal carcinogenic invasion (a and
b) and/or peri hepatic carcinogenesis (c). Animals treated with the
highest dose did not present any invasion.
Found at: doi:10.1371/journal.pone.0004409.s002 (4.47 MB EPS)
Table S1
Found at: doi:10.1371/journal.pone.0004409.s003 (0.05 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0004409.s004 (0.02 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0004409.s005 (0.02 MB
DOC)
Table S4
Found at: doi:10.1371/journal.pone.0004409.s006 (0.02 MB
DOC)
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